Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1997 2
1998 8
1999 3
2001 1
2002 1
2003 2
2006 1
2009 1
2010 3
2011 1
2012 3
2013 4
2014 5
2015 3
2016 3
2017 3
2018 3
2019 5
2020 6
2021 3
2022 3
2023 1
2024 2
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
[Blue lips].
Rantalaiho V, Lehto P, Salonen T. Rantalaiho V, et al. Duodecim. 1999;115(19):2117,2119. Duodecim. 1999. PMID: 11958167 Finnish. No abstract available.
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.
Pons M, Georgiadis S, Hetland ML, Ahmadzay ZF, Rasmussen S, Christiansen SN, Di Giuseppe D, Wallman JK, Pavelka K, Závada J, Codreanu C, Glintborg B, Loft AG, Santos H, Lourenço MH, Nissen MJ, Ciurea A, Kuusalo L, Rantalaiho V, Michelsen B, Mielnik P, Pirkmajer KP, Rotar Z, Gudbjornsson B, Palsson O, van der Horst-Bruinsma I, van de Sande M, Castrejón I, Macfarlane GJ, Laas K, Østergaard M, Ørnbjerg LM. Pons M, et al. Among authors: rantalaiho v. J Rheumatol. 2025 Jun 1;52(6):572-582. doi: 10.3899/jrheum.2024-0920. J Rheumatol. 2025. PMID: 39892891 Free article.
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries.
Ciurea A, Kissling S, Götschi A, Ørnbjerg LM, Rasmussen SH, Tamási B, Möller B, Nissen MJ, Glintborg B, Loft AG, Scherer A, Bräm R, Pavelka K, Závada J, Dias JM, Valente P, Gudbjornsson B, Palsson O, Rantalaiho V, Peltomaa R, Codreanu C, Mogosan C, Iannone F, Sebastiani M, Jones GT, Macfarlane GJ, Castrejon I, Rotar Z, Michelsen B, Wallman JK, van der Horst-Bruinsma I, Distler O, Østergaard M, Hetland ML, Micheroli R, Ospelt C. Ciurea A, et al. Among authors: rantalaiho v. Arthritis Res Ther. 2025 Jan 31;27(1):18. doi: 10.1186/s13075-025-03488-w. Arthritis Res Ther. 2025. PMID: 39891200 Free PMC article.
Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.
Hiltunen J, Parmanne P, Sokka T, Lamberg T, Isomäki P, Kaipiainen-Seppänen O, Peltomaa R, Uutela T, Pirilä L, Taimen K, Kauppi MJ, Yli-Kerttula T, Tuompo R, Relas H, Kortelainen S, Paalanen K, Asikainen J, Ekman P, Santisteban A, Vidqvist KL, Tadesse K, Romu M, Borodina J, Elfving P, Valleala H, Leirisalo-Repo M, Rantalaiho V, Kautiainen H, Jokiranta TS, Eklund KK; FinADASpA Study Group. Hiltunen J, et al. Among authors: rantalaiho v. Rheumatol Int. 2022 Jun;42(6):1015-1025. doi: 10.1007/s00296-021-04955-8. Epub 2021 Aug 6. Rheumatol Int. 2022. PMID: 34357455 Free PMC article.
65 results